Engineered immune cells take on lupus in early trial
NCT ID NCT07266337
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new treatment called CD19/BCMA CAR-T cell therapy for adults with refractory systemic lupus erythematosus (SLE) that hasn't improved with standard treatments. About 24 participants will receive a single infusion of their own engineered immune cells and be closely monitored for safety and disease activity for up to 2 years. The goal is to see if this approach can reduce lupus symptoms and possibly allow patients to stop other medications, though lifelong management may still be needed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SLE - SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The General Hospital of Western Theater Command
Chengdu, Sichuan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at childhood autoimmune diseases
- Off-the-Shelf CAR-Ts take on lupus and more
- Engineered immune cells take on lupus kidney disease
- New lupus drug candidate enters human safety testing
- Engineered immune cells take on lupus and scleroderma in new trial
- New lupus drug candidate cenerimod tested in chinese patients